This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
The possibility of the federal court system consolidating cases filed by victims suffering liver problems from Tylenol has generated increased numbers of inquiries about legal representation.
San Diego CA (PRWEB) March 03, 2013
Resource4thePeople announced today that it is informing consumers who may have suffered liver damage as a result of the use of Tylenol and other acetaminophen medications that an important court date has been scheduled.
The United States Judicial Panel on Multidistrict Litigation has agreed* to hear a petition from plaintiffs who have filed Tylenol liver failure allegation lawsuits to consolidate those lawsuits before a single federal judge.
The hearing on the petition is scheduled for March 21, 2013 at the United States Courthouse Annex, Courtroom 15B, 333 West Broadway, San Diego, Ca.
“This is an important milestone in the progress of a growing number of lawsuits claiming that the use of Tylenol and other acetaminophen-based pain-killers can put patients at significantly increased risk of suffering life-threatening liver damage,” said Resource4thePeople.
“We have been receiving a steadily increasing number of inquiries from Tylenol victims who say they have been having difficulty receiving information about the progress of this litigation and what their legal rights may be.
“Resouce4thePeople remains committed to providing updates about the progress of this litigation and is also providing free legal consultations to individuals who may have suffered liver damage from Tylenol use. We welcome their inquiries and will investigate the merits of all such cases.”
This announcement stems from the increasing number of cases involving Tylenol and other pain-killers containing acetaminophen and a health warning from the U.S. Food and Drug Administration, which also has identified liver failure cases stemming from the pain-killers, said Resource4thePeople.
“We are stepping up our efforts to make the public more aware of dosing problems that can exist with the use of Tylenol and other acetaminophen-based medications because many people may not be aware of these dangers,” said Resource4thePeople, which cited the following health warning issued by the FDA:
“Acetaminophen is the generic name of a drug found in many common brand name OTC products such as Tylenol, as well as prescription products such as Vicodin and Percocet. Acetaminophen is an important drug, and its effectiveness in relieving pain and fever is widely known. This drug is generally considered safe when used according to the directions on its labeling. But taking more than the recommended amount can cause liver damage, ranging from abnormalities in liver function blood tests, to acute liver failure, and even death.”**
The petition to the United States Judicial Panel on Multidistrict Litigation states that “Centralization and consolidation of the Tylenol is beneficial to both plaintiffs and defendants, and reduces duplicative discovery, avoids conflicting rulings from different judges.”
Attorneys for the plaintiffs requested that the 28 cases currently pending against McNeil PPC Inc., McNeil Consumer Healthcare and Johnson & Johnson be coordinated and consolidated at the federal courthouse in Philadelphia.
“All of the products liability cases referenced by the plaintiffs’ lawyers allege that McNeil marketed and sold its over-the-counter Tylenol products in a manner that concealed the margin of risk of liver toxicity and liver failure,” according to the filings for the petition.
The Pennsylvania Record, the state’s legal newspaper, reported that a total of 21 of the 28 cases are currently pending in the U.S. District Court for the Eastern District of Pennsylvania, and although they were originally assigned randomly to various judges within that district, they have all since been reassigned by the court’s chief judge to U.S. District Judge Lawrence F. Stengel.***
The Record also reported that other Tylenol liver damage allegation actions have been filed in eight different federal courts in Mississippi, California, New York, Florida, New Jersey and Massachusetts.
If the federal judicial panel decides to consolidate the cases before a single judge that judge would oversee pre-trial evidence-gathering, legal motions and settlement talks in the litigation.
The same judge also would decide on whether to grant class-action status to the litigation based on judicial efficiency, common claims by plaintiffs and common defendants.
Resource4thePeople said that the consultations with Tylenol liver damage allegation attorneys can provide legal options to men, women and children who allegedly have suffered liver damage or failure due to their use of Tylenol and other products containing the ingredient acetaminophen.
Legal assistance also is available to those who may have lost a loved one and may be seeking information about the facts involved in a wrongful death.
Resource4thePeople also is alerting consumers to a 2011 Drug Safety Communication about pain-killers containing acetaminophen in which the FDA announced that Tylenol and other drug manufacturers were being asked to limit the strength of acetaminophen in prescription drug products out of concern about liver problems.****
Soon afterward, McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson, was among the companies announcing that it was reducing the recommended maximum daily dose of its Tylenol products.
Resource4thePeople said that it is imperative that consumers familiarize themselves with the current dosage requirements established by the FDA, which has warned that against overusing the medication in this flu season.
Acetaminophen is contained in many of the most popular cold and flu remedies, aids for sleeping, relief mixtures for headaches as well as being an ingredient in prescribed pain-killers.
Consumer4thePeople is urging consumers to complete familiarize themselves with the warning labels on such medications because these dosage changes that have been made at the direction of the FDA.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10490100.htm